
MicroPort
Founded Year
2016Stage
PIPE - III | IPOAbout MicroPort
MicroPort (00853. HK) operates as a medical device company focusing on manufacturing, and marketing medical devices globally. It specializes in areas including cardiovascular, orthopedic, electrophysiology, endovascular, neurovascular, surgical, diabetes care and endocrinal management, and others. The company was founded in 2016 and is based in Shanghai, China.
MicroPort Patents
MicroPort has filed 3 patents.
The 3 most popular patent topics include:
- Implants (medicine)
- Orthopedic surgical procedures
- Bone fractures

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/30/2021 | Plastic surgery, Neurological disorders, Surgical removal procedures, User interfaces, Cosmetic surgery | Application |
Application Date | 4/30/2021 |
---|---|
Grant Date | |
Title | |
Related Topics | Plastic surgery, Neurological disorders, Surgical removal procedures, User interfaces, Cosmetic surgery |
Status | Application |
Latest MicroPort News
Sep 28, 2023
Search jobs 28-Sep-2023 FMI Unveils Coronary Stents Market’s Resilient 5.1% CAGR Journey Towards US$ 51.2 Million by 2032 The global Coronary Stents Market is poised to achieve a valuation of US$ 51.2 million by 2032, with a steady CAGR of 5.1% anticipated during the period spanning 2022 to 2032. In the year 2022, the market is expected to attain an estimated worth of US$ 33.36 million. This growth is driven by several factors, including the growing elderly population, an increasing prevalence of cardiovascular diseases, and lifestyle-related ailments such as diabetes, obesity, and other medical conditions. The increasing awareness of the manifold benefits associated with stenting procedures, such as the significant enhancement of blood flow and protection against further damage to the heart muscle, is a pivotal driver of market expansion. Stenting also offers a means to ameliorate heart disease symptoms, including angina and shortness of breath, ultimately reducing the necessity for coronary bypass surgery. Consequently, both surgeons and patients, given its minimally invasive nature and relatively brief post-operative recovery period, favor stenting. Claim You’re Report – Featuring Captivating Visuals Inside! Furthermore, a rise in the global geriatric population is leading to a larger patient pool with serious cardiovascular diseases. Again, hypertension is arising as a grave public health concern. Obesity, too, adds to this burden as one of the primary risk factors accountable for different cardiovascular diseases worldwide. Coronary stenting is prescribed to patients who are suffering from coronary artery blockage. Though angioplasty is the first line of treatment for patients with acute coronary artery blockages the number of patients undergoing stenting has been increasing steadily over the last ten years. This is owing to the rise of outpatient coronary stenting procedures, which shortens long hospital stays. Additionally, a large number of cardiologists prescribing stenting procedures for patients with CAD is a prime factor that will likely fuel revenue growth of the coronary stent market during the forecast period. “Increasing cases of lifestyle diseases like obesity and diabetes often result in heart issues which, in turn, supplements the global growth of the coronary stents market over the forecast period,” says an FMI analyst. Examining the key assumptions of the study: Ask and Receive. Rising awareness of the benefits associated with stenting will strengthen market prospects. Prevalence of alternative treatment methods, product failure, and recalls are certain factors that may hamper market growth. Growing cases of coronary artery diseases propel the coronary stent market in the United States. Favorable government support for the healthcare sector will present new market opportunities in China. Competitive Landscape Abbott, Medtronic, Boston Scientific Corporation, Terumo Corporation, B Braun Melsungen AG, Biotronik, Stentys SA, MicroPort Scientific Corporation, C. R. Bard, Inc., and Cook Medica among others are some of the major players in the coronary stents market profiled in the full version of the report. Key market players are focusing on product upgrades and offering new features to meet the rising consumer demand. These organizations are employing strategies like new product releases, partnerships, collaborations, mergers, and acquisitions to gain a competitive advantage. More Insights into Coronary Stents Market Report In its latest report, FMI offers an unbiased analysis of the global coronary stents market, providing historical data from 2016 to 2021 and forecast statistics for 2022 to 2032. To understand the global market potential, growth, and scope, the market is segmented based on product type (drug-eluting stent (DES), bare metal stent (BMS), bioresorbable vascular stent (BVS)), raw material (cobalt chromium, stainless steel, platinum-chromium, nickel-titanium, polymer), end user (hospitals, ambulatory surgical centers, cardiac catheterization laboratories), and region. Ignite Change: Get Your Customized Impactful Report Now! According to the latest FMI reports, based on region, China’s coronary stent market will likely exhibit an impressive growth rate during the observation period due to favorable government support for the healthcare sector. The coronary stent market in the United States is anticipated to demonstrate substantial growth over the forecast period. The rising prevalence of coronary artery disease is spurring the demand for interventional cardiology treatment in this country. Sedentary lifestyles, smoking, poor dietary habits, and pollution often contribute to increasing cases of cardiovascular diseases. All of these factors are expected to drive the demand for the target market during 2022-2032. Key Segments Covered in the Coronary Stents Industry Analysis By Product:
MicroPort Frequently Asked Questions (FAQ)
When was MicroPort founded?
MicroPort was founded in 2016.
Where is MicroPort's headquarters?
MicroPort's headquarters is located at 1601 Zhangdong Road , Shanghai.
What is MicroPort's latest funding round?
MicroPort's latest funding round is PIPE - III.
Who are the investors of MicroPort?
Investors of MicroPort include Timesbole, Zhangke Herun, Chengwei Chuangban, Hillhouse Capital Management, L Squared Capital Partners and 16 more.
Who are MicroPort's competitors?
Competitors of MicroPort include Ceryx Medical.
Compare MicroPort to Competitors

Impulse Dynamics is a medical device company dedicated to transforming the treatment of chronic heart failure. The company has additional offices in Stuttgart, Germany; Orangeburg, New York, and Willemstad, Curacao. Impulse Dynamics was founded in 1998 and is based in Mount Laurel, New Jersey.
Abbott develops medical devices and solutions for cardiovascular conditions. The company's products represent solutions with cardiac rhythm management technologies. It was founded in 2018 and is based in Abbott Park, Illinois.

Ceryx Medical develops a bioelectronic technology that could change the way diseases such as heart failure are treated. Employing biomimetic design principles and patented electronics, Ceryx has created a range of smart bioelectronic medical devices that speak the same language as the human body. The company was founded in 2016 and is based in Cardiff, Wales.

Medtronic (NYSE: MDT) is a healthcare solutions company. It develops technologies, including implantable mechanical devices, drug and biologic delivery devices, and powered and advanced energy surgical instruments. The company was founded in 1949 and is based in Minneapolis, Minnesota.

Boston Scientific (NYSE: BSX) develops and manufactures medical devices. It provides critical care products, electrophysiology products, gastroenterology products, pulmonology products, and more. The company offers pacemakers, defibrillators, coronary stents, and others. Boston Scientific caters to medical practitioners, patients, and research and development students. The company was founded in 1979 and is based in Marlborough, Massachusetts.